Enlivex is a clinical stage biopharmaceutical company developing Allocetra™
a universal, off-the-shelf cell therapy platform designed to restore the homeostatic state of macrophages, for the treatment of inflammatory diseases.
We believe that by harnessing the natural healing power of macrophages, our new therapeutic modality platform may lead to a breakthrough in the treatment of various inflammatory diseases and improve the lives of many patients who currently do not have an effective treatment for their condition.
Our pioneering Allocetra™ cell-based therapy platform breaks with old paradigms, designed to treat numerous acute and chronic conditions through a radically different clinical approach.
Our Vision
Our vision is to provide therapeutic solutions to patients who suffer from life threatening or debilitating diseases, which have no treatment alternatives.
Our Mission
Our mission is to lead the development and commercialization of a robust pipeline of groundbreaking macrophage reprogramming therapies to fulfill our vision to improve patients’ lives.
The Enlivex: where expertise and innovation flourish under proven leadership
Enlivex was founded to advance the pioneering research of our co-founder, Professor Dror Mevorach, an expert in immune activity, macrophage activation, and the clearance of apoptotic (dying) cells. The discovery that normal apoptotic cells create an anti-inflammatory and homeostatic immune state in macrophages and dendritic cells through multiple mechanisms, opened the door to developing a new therapeutic modality. This novel approach harnesses the natural healing power of macrophages to treat various acute and chronic inflammatory diseases, and provides a potential way to treat inflammatory states at their origin.
For three years, Professor Mevorach developed the manufacturing process for the groundbreaking apoptotic cell-based platform, Allocetra™. In 2010, we successfully conducted our first I/II clinical study, evaluating our therapy as a prophylaxis treatment for graft-versus-host disease in myeloablative HLA-matched allogeneic bone marrow transplantation.
Following their success of creating shareholder value with PROLOR Biotech, three key members reunited to advance Professor Mevorach’s research, joining Enlivex in 2015. Building on their experience partnering with Pfizer to commercialize ngenla, PROLOR’s lead product that has received marketing approval in 43 countries to date, including U.S., Europe and Japan, they assembled a team of experts to further optimize the development of Allocetra™ drug product.
Since then, we have continuously refined and enhanced Allocetra™, evolving it from its first-generation liquid formulation derived from HLA-matched donors, through a second iteration utilizing non-matched allogeneic apoptotic cells, to its current form.
Today, Allocetra™ stands as a fully off-the-shelf, frozen, and cost-effective therapeutic product, readily available for clinical use. It has been successfully administered to over 150 patients with favorable safety profile and no drug related severe adverse effects.